focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,168.00
Ask: 12,170.00
Change: -74.00 (-0.60%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Closing snapshot: What's not to like?

Tue, 15th Sep 2020 17:03

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni
(danilo.masoni@thomsonreuters.com) and Stefano Rebaudo (stefano.rebaudo@thomsonreuters.com) in
Milan.

CLOSING SNAPSHOT: WHAT'S NOT TO LIKE? (1546 GMT)

The STOXX 600 ends the day with a 0.8% rise but more than the percentage gain, the overall
mood was clearly upbeat.

Good indicators from China had already laid the ground for some risk-on trading when the
session started with a pleasant surprise for Fiat and Peugeot shareholders.

The terms of the car makers' merger were changed but still looked like a good deal, judging
by the 9% gain in Milan and the 2% rise in Paris.

"It's a clever move which should make everyone happy", said a London-based merger arbitrage
fund manager with a position on the deal.

But there was more good news to come, notably in the retail space with H&M rebounding from
its COVID-19 slump and Ocado surfing on e-retail.

Talking about the UK, speculation about more stimulus to support the labour market also
lifted spirits.

Another morale booster came in the form of an unexpected jump in investor sentiment in
Germany.

Then Wall Street and big tech rising in the afternoon gave a final helping hand to Europe.

In terms of sectors, interesting to note that Healthcare came back in positive territory
year-to-date with a handsome 1.7% rise on the day.

The battered banking sector is the only segment in the red, down about 0.9% which puts its
performance in 2020 down to -37%.

(Julien Ponthus)

*****

STOXX EARNINGS: A TAD WORSE BEFORE IT GETS A TAD BETTER (1356 GMT)

Analysts are getting just a tad less optimistic short term for STOXX 600 earnings.

Expectations for Q3, Q4 and Q1 2021 have been on a gentle downward trend for a while now but
on the bright side, the rebound in profits seen later in 2021 keeps improving toward Q3. A tad.
Here's the latest chart from Refinitiv:

As you can see, compared with the same chart published on September 1, expectations for a
steep V-shaped recovery are indeed giving ways to a more progressive recovery stretching towards
the end of 2021:
(Julien Ponthus)

*****

IMMUNOLOGY TO THE PEOPLE (1221 GMT)

It may sound obvious but COVID-19 is indeed going to give a nice shot in the arm to the
global vaccines market.

Jefferies has looked into it and sees the business surging above $50 billion by 2025 from
$36 billion currently.

"COVID-19 has introduced immunology to the masses & heightened infectious disease awareness,
with governments also reassessing preparedness & health economics of prevention. We see this
kick-starting a new era for vaccines," they say.

(Danilo Masoni)

*****

STILL LOVE FOR UK COMPANIES (1155 GMT)

As the UK and the EU seem far from reaching a Brexit deal to shape their relationships after
a transition period ends in December, one would think it would be best to keep distance from
British equities, which has lagged global stocks.

Well, UBS disagrees saying it likes the UK equity market for its "attractive valuation" at
15.4x 12-month trailing P/E, which is a 30% discount to MSCI All-Country World.

The Swiss bank is also confident there is plenty of time to reach a Brexit deal.

"We think that the political and economic incentives point to an agreement eventually being
reached" it says in its House View note.

Then, it sees a strong bounce back next year.

"We expect earnings growth to fall substantially this year, but by 2021 we anticipate a
robust rebound driven by an economic bounce-back and a recovery in the oil price".

(Joice Alves)

*****

SO MUCH FOR TINA! EM RETURNS ALIVE AND KICKING (1135 GMT)

The extent of the demise of real returns in developed world bond markets is a hotly-debated
topic which has pretty much fed the TINA (there is no alternative to stocks) narrative for the
last few years.

But looking beyond developed markets, real returns are very much alive in emerging market.

JP Morgan's Government Bond Index Emerging Markets Global Diversified, which tracks emerging
local currency debt, is up around 2.8% during the quarter to date, compared to 0.1% for one to
three year U.S. Treasury bonds.

South Africa, Turkey, Indonesia and Brazil offer the highest cushion in real carry, as
measured by nominal local government bond yields adjusted for 1-year-ahead inflation
expectations compared to U.S. dollar 3-month Libor, HSBC said in a research note.

Risk-adjusted real carry is most favourable for Indonesia, South Africa and Russia, the bank
noted.

"The Brazil curve is the second-steepest EM high-yielding curve, but this analysis suggests
that there is little compensation for extending along the curve," André de Silva, HSBC's head of
global EM rates research, wrote in the note.

"We prefer having exposure to Russia (buy 5yr OFZs) and Indonesia (i.e. buy 5yr IndoGBs)
rather than South Africa or Brazil."

Carry after being risk-adjusted relegates Turkey to being among the emerging market
high-yielders providing the least cushion, the bank said, outlying concerns about the recent
acceleration in FX depreciation and backdoor policy tightening.

India was the least favourable on a risk-adjusted basis, the bank added. HSBC advised
positioning for higher rates in India and a steeper curve, as well as an easing in the potency
of the bond buying via the central bank's auctions.

(Tom Arnold)

*****

VALUE IS A EUROPE THING (1041 GMT)

Though it has not been working much lately, more analysts are still advocating a call for
value, but mostly in value-heavy Europe.

The value/growth rate has been essentially flat since April while it has staged a small
resurgence recently with value outperforming growth by around 3% since September 2, according to
Credit Suisse data.

Here are the reasons to believe that it is value time: It tends to follow PMIs with a
three-month lag; the euro seems to be under control with the ECB worried about its
strengthening; the price to book of value relative to growth in Europe is now two standard
deviations below its average, a Credit Suisse analyst note says.

“We believe that in Europe, the absence of megacap tech will allow European value to
outperform, and thus we remain overweight,” it adds.

While “we see scope for the equity risk premium to decline, underpinning the attractions of
the big cap tech.”

Credit Suisse highlights Brenntag, Siemens and Smiths Group,
while shares in CRH, Lafarge, Enel, Smurfit Kappa RWE
appear cheap.

(Stefano Rebaudo)

*****

WHAT’S IN A CORPORATE EARNINGS DATE? (1007 GMT)

Plenty, if data analytics firm Raven Pack is to be believed.

Advances or delays in earnings announcement dates can be predictive of positive or negative
results and investment strategies based on such date changes can deliver sizeable returns,
according to Peter Hafez, chief data scientist at Raven Pack.

Investors have long used traditional fundamental methods to forecast company earnings.
Intensifying competition and the alternative data explosion over the past decade have led to
rapid adoption of novel approaches in forecasting stock performance.

Company executives often use strategic timing to distribute earnings results. Some studies
have shown that earnings delays may signal weak performance, while advancing the date may be a
sign of good news.

Using earnings calendar change records for over 8,000 stocks globally since 2006 with a
central focus on the U.S. stock market, data scientists at the firm found portfolio investment
strategies that bought after advances, and sold after delays, produced annual excess returns of
8.4%, for portfolios of mid to large-cap stocks and 18.6% for small-caps.

However, mid-to large cap companies are more prone to deeper losses for earnings date delays
while small cap gains are more amplified for earning dates advances. Typically, the
outperformance ebbs quickly within a few days, the study found. For a link to the study, see https://www.ravenpack.com/research/trading-earnings-calendar/

(Saikat Chatterjee)

*****

NOT ALL MERGERS FALL APART (0928 GMT)

Let's face it: completing merger deals has become more challenging in this new COVID-19
world.

Take LVMH/Tiffany in luxury and Fiat Chrysler/PSA in the automotive sector. Both deals were
bigly challenged by the turmoil created by the pandemic but while LVMH resolved to call off the
deal (with political interference playing crucial part in the decision), the merger to create
the world's No. 4 carmaker is nevertheless going ahead.

But that comes with a cost, which seems investors are willing to pay, and may raise further
hopes that M&A could recover after activity collapsed in the second quarter of 2020.

To preserve cash, FCA will nearly halved its pre-merger special dividend to 2.9 billion
euros and France's PSA will in turn postpone the planned spinoff of its 46% stake in parts maker
Faurecia until after the merger's closing.

The decision might have been a tough one to take but after all that will result in a
financially stronger group, which combined with sharp increase in the synergy target explains
why their shares reacted positively at the start of trading.

It looks that investors are looking beyond any short term gains, preferring synergies
tomorrow than dividends today.

"The higher value of the industrial synergies more than offset any revision of terms," says
Equita.

PSA shares hit a 6-month high before retreating to trade down 1% on the day, while FCA
shares are up 6%.

(Danilo Masoni)

*****

STOCK PRICES RANGEBOUND UP TO END 2020 (0910 GMT)

It won’t be all about virus trajectories and macro data for the stock market as there is a
lot going on, starting with the U.S. presidential elections.

After UBS yesterday said the stock market is fragile but it was confident that investors
will turn their focus on the positives soon, JP Morgan analysts sound even more cautious.

They line up risks that equities will face and say that the STOXX 600 index will remain
rangebound by end 2020.

This is in line with our Aug 26 poll which showed investors were on average expecting the
STOXX 600, currently at 370 points, to end the year at 375 points.

On the U.S, presidential election front, the real danger is the vote ending along the lines
of the Bush versus Gore Florida recount in 2000, leading to a ”legislative paralysis for some
time,” a JP Morgan research note says.

Foreign trade is going to be an issue whoever wins as “polls suggest that the unfavourable
views of China have become firmly bipartisan,” it adds.

Technicals are not helping as positioning is far from depressed, with “short interest and
put/call ratios at lows.”

Besides, fundamentals could soften if labour market improvement stalls and if the virus
dampens the recovery; default rates might spike; geopolitical risks are in place with “Brexit,
Russia, Iran and other.”

“We do not think that any of the above risks should necessarily be seen as a clear base
case, but the potential is that some of them might be realized.”

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: BIG MOVES UNDER THE FLAT SURFACE (0715 GMT)

European shares are off to a cautious start but under the flat surface there are some big
moves.

H&M is rallying 10% after its Q3 profit beat expectations, while in the auto sector
FCA is up 7% and PSA is gaining 1% after they revised the terms of their
merged in a bid to conserve cash. The revision meant that PSA will postpone the sale of its
stake in parts maker Faurecia, which is down 8.6%.

Strong retail sales are pushing online supermarket Ocado up 4.7%.

After initial gains at the open, the STOXX 600 has now pulled back, trading down
0.10%.

(Danilo Masoni)

*****

PSA/FCA, PAYMENTS DEALS, BANKS AND VACCINE NEWS ON OUR RADAR (0639 GMT)

While rangebound trading looks set to continue in typical pre-Fed fashion -- EUROSTOXX 50
futures are just flat -- on the corporate front some dealmaking headlines could liven up the
session, along with fresh vaccine updates.

PSA and Fiat Chrysler (FCA) have revised the terms of their planned
merger to conserve cash. FCA will cut to 2.9 billion euros the cash portion of a 5.5 billion
euro special dividend, while the French group will postpone to after the merger's closing the
planned spinoff of its 46% stake in parts maker Faurecia.

In the buoyant payments industry, Klarna Bank AB has raised $650 million at a valuation of
$10.65 billion from investors led by Silver Lake, while in Italy la Repubblica
reports that Nexi and smaller rival SIA are nearing a preliminary agreement for a
merger

In banks, one day after talk of a potential tie-up between Credit Suisse and UBS
, the focus may turn to Spain. A source said Caixabank is
considering a bid for Bankia that could value it at around 4 billion euros -- a
premium of between 15% and just above 20% over Bankia's average 3-month share price.

Vaccine news does not seem so bright today with sources saying AstraZeneca's
COVID-19 vaccine trial remains on hold in the United States pending a U.S. investigation into a
serious side effect in Britain even as other trials of the vaccine resume.

Shares in Zurich-lised Siegfried however rose 1.9% in premarket after a contract
with BioNTech to fill and pack a potential COVID-19 vaccine, while Lonza also gained
after unveiling a collaboration deal to expand the manufacturing of Humanigen's COVID-19
therapeutic candidate Lenzilumab.

Meantime in the UK, the pandemic generated huge demand for online deliveries, sending UK
online supermarket Ocado's retail sales in the 13 weeks to Aug. up 52%.

We'll also keep an eye on Daimler after courts documents showed it will pay $2.2
billion violating U.S. clean air laws and to resolve claims from 250,000 U.S. vehicle owners.

(Danilo Masoni)

*****

MORNING CALL: A CHOPPY DAY AHEAD? (0530 GMT)

European bourses look set for another choppy session today with futures moving between flat
and slightly lower, while spreabetters' calls are pointing to marginal gains.

The main event of this week is the Fed's two-day policy meeting which could help provide
fresh direction, while the German ZEW may draw some attention later today.

The day in Asia saw Chinese stocks rise following data that showed industrial output
expanded for a fifth straight month in August, while the Nikkei pulled back.

Meantime, U.S. futures rose slightly.

Futures for the S&P 500 were up 0.3%, while EUROSTOXX 50 futures eased 0.2%

(Danilo Masoni)

*****

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.